Topic
Topic
Moderna and Merck said their mRNA cancer vaccine succeeded in a late-stage melanoma trial, per statnews.com, but effect size, endpoint detail and a regulatory timeline remain undisclosed.
Phase 3 ICONIC-TOTAL data show oral icotrokinra achieved IGA 0/1 in 70% of psoriasis patients at Week 112, with 89% genital clear…
Phase 3 results from 412 Chinese patients show oturkibart, an IL-4Rα monoclonal antibody, drove 74.5% of participants to a 4-poin…
In phase 3 OptIMMize-1 data published in the British Journal of Dermatology, risankizumab matched ustekinumab on most endpoints a…
Denifanstat, an oral FASN inhibitor, sustained acne lesion reductions through 52 weeks in a Phase 3 open-label extension, per Der…
Zasocitinib delivered superior skin clearance versus deucravacitinib in a Phase 3 head-to-head plaque psoriasis trial, raising th…
A personalized neoantigen vaccine met its primary endpoint, reducing melanoma recurrence risk after resection in a phase 3 trial…